title: Role of gut microflora in the development of obesity and insulin resistance following high-fat diet feeding.
abstract: A recent growing number of evidences shows that the increased prevalence of obesity and type 2 diabetes cannot be solely attributed to changes in the human genome, nutritional habits, or reduction of physical activity in our daily lives. Gut microflora may play an even more important role in maintaining human health. Recent data suggests that gut microbiota affects host nutritional metabolism with consequences on energy storage. Several mechanisms are proposed, linking events occurring in the colon and the regulation of energy metabolism. The present review discusses new findings that may explain how gut microbiota can be involved in the development of obesity and insulin resistance. Recently, studies have highlighted some key aspects of the mammalian host-gut microbial relationship. Gut microbiota could now be considered as a "microbial organ" localized within the host. Therefore, specific strategies aiming to regulate gut microbiota could be useful means to reduce the impact of high-fat feeding on the occurrence of metabolic diseases.
authors.affiliation: Unit of Pharmacokinetics, Metabolism, Nutrition and Toxicology, université catholique de Louvain, avenue E. Mounier, 73/69, 1200 Brussels, Belgium. patrice.cani@uclouvain.be
authors.forename: P D
authors.initials: PD
authors.lastname: Cani
authors.forename: N M
authors.initials: NM
authors.lastname: Delzenne
authors.forename: J
authors.initials: J
authors.lastname: Amar
authors.forename: R
authors.initials: R
authors.lastname: Burcelin
mesh_terms: D000818:Animals; D001419:Bacteria / Q000187:drug effects / Q000378:metabolism; D018407:Bacterial Physiological Phenomena; D001644:Bifidobacterium / Q000502:physiology; D001835:Body Weight; D003924:Diabetes Mellitus, Type 2 / Q000453:epidemiology / Q000209:etiology / Q000382:microbiology / Q000503:physiopathology; D004040:Dietary Carbohydrates / Q000494:pharmacology; D004041:Dietary Fats / Q000009:adverse effects* / Q000494:pharmacology; D004043:Dietary Fiber / Q000627:therapeutic use; D004734:Energy Metabolism; D006801:Humans; D007249:Inflammation / Q000209:etiology / Q000382:microbiology; D007333:Insulin Resistance; D007422:Intestines / Q000382:microbiology*; D018950:Lipopolysaccharide Receptors / Q000235:genetics / Q000502:physiology; D051379:Mice; D018345:Mice, Knockout; D008820:Mice, Obese; D009765:Obesity / Q000453:epidemiology / Q000209:etiology* / Q000382:microbiology / Q000503:physiopathology; D011134:Polysaccharides / Q000494:pharmacology; D015995:Prevalence
chemical_list: D004040:Dietary Carbohydrates; D004041:Dietary Fats; D004043:Dietary Fiber; D018950:Lipopolysaccharide Receptors; D011134:Polysaccharides